A cross-sectional observational study to establish the association between ECOG performance status and age and administration of doublet or triplet chemotherapy containing Xeloda® (capecitabine) in advanced gastric cancer patients. Eur J Oncol [Internet]. 2014 Jun. 4 [cited 2024 Jul. 18];18(4):173-80. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/2443